Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a clinical-stage biotechnology company developing therapies for kidney disease and other medical needs. Its two product candidates are oxylanthanum carbonate (OLC), an investigational phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis,… From the company’s description.
In fiscal 2025, Unicycive Therapeutics, Inc. reported a net loss of $26.55M. Operations used $31.32M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Unicycive Therapeutics, Inc. does
In the company’s own words
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a clinical-stage biotechnology company developing therapies for kidney disease and other medical needs. Its two product candidates are oxylanthanum carbonate (OLC), an investigational phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a candidate for acute kidney injury. OLC uses nanoparticle technology and is designed as a swallowable tablet intended to reduce pill burden; its U.S. drug application is under FDA review. The company licenses drug technologies and pursues their development, regulatory approval and commercialization, initially focusing on U.S. markets while using regional licensing partners internationally. It has licensed OLC rights in Greater China to Lee’s Pharmaceutical Holdings and in select Asian markets to Lotus Pharmaceutical. Unicycive was founded in 2016, and its two programs originated with Spectrum Pharmaceuticals and Sphaera Pharma before being licensed or acquired by the company. It reports one business and has no marketed products or product revenue. Its website is www.unicycive.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MOUNTAIN VIEW, CA
- Fiscal year end
- December
- CIK
- 1766140
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Unicycive Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Unicycive Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Unicycive Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Unicycive Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Unicycive Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”